Inventiva S.A. IVEVF

Company Overview

Inventiva S.A. is a French clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), rare diseases, and other conditions with significant unmet medical need. The company operates within the biotechnology and pharmaceutical industries and is publicly traded on Euronext Paris and quoted in the U.S. OTC market under the ticker IVEVF. Inventiva’s primary value driver has been its lead investigational therapy, lanifibranor, a pan-PPAR agonist being evaluated for MASH and related metabolic disorders. The company has also conducted research in fibrosis, oncology, and lysosomal storage disorders through internal programs and collaborations.

Inventiva was founded in 2012 in Daix, France, following the spin-out of research assets from Abbott Laboratories’ French operations. Since its formation, the company has evolved from a broader discovery-stage biotechnology platform into a more focused late-stage clinical development company centered on liver disease therapeutics. Inventiva’s positioning is supported by its expertise in nuclear receptor biology, fibrosis research, and drug discovery capabilities, as well as by regulatory designations and partnerships supporting development of lanifibranor. Public disclosures in SEC filings and company annual reports consistently identify MASH as the company’s core strategic focus.

Business Operations

Inventiva’s operations are primarily organized around its therapeutic development programs, with revenue historically derived from collaboration agreements, milestone payments, research partnerships, and financing activities rather than commercial product sales. Its principal business program is lanifibranor, which has advanced into late-stage clinical development for MASH. The company has also maintained earlier-stage assets and discovery programs targeting fibrosis and metabolic diseases, although portfolio prioritization has increasingly concentrated resources on liver disease indications. Inventiva operates research and development facilities in France and conducts multinational clinical trials through collaborations with contract research organizations, hospitals, and academic centers.

The company’s operational footprint includes activities across Europe, the United States, and other international clinical trial regions. Inventiva has previously entered into strategic collaborations with pharmaceutical and biotechnology organizations to support research, manufacturing, and development activities. Publicly disclosed partnerships have included work with AbbVie, Boehringer Ingelheim, and academic institutions connected to metabolic and fibrotic disease research. Inventiva also controls proprietary intellectual property related to PPAR modulation and fibrosis pathways, which forms a central component of its development strategy.

Strategic Position & Investments

Inventiva’s strategic direction is centered on advancing lanifibranor through pivotal clinical development for MASH, an area that has attracted substantial pharmaceutical investment due to the lack of broadly effective approved therapies historically available for advanced liver fibrosis associated with metabolic disease. The company has emphasized differentiation through the drug candidate’s pan-PPAR mechanism, which is intended to address fibrosis, inflammation, and metabolic dysfunction simultaneously. Inventiva has sought regulatory engagement with U.S. and European authorities to support development pathways and potential future commercialization.

The company has raised capital through public offerings, debt financing arrangements, and strategic investments to fund late-stage clinical programs. Inventiva has also invested in expanding manufacturing readiness and global trial infrastructure related to lanifibranor development. In addition to its lead program, the company has maintained selective investments in discovery platforms and earlier-stage therapeutic research, though public filings indicate that resource allocation remains heavily weighted toward MASH. Data regarding future commercialization partnerships or acquisition activity remains inconclusive based on available public sources.

Geographic Footprint

Inventiva is headquartered in Daix, France, with operational and clinical activities extending across multiple international markets. The company’s clinical development programs have involved sites in Europe, North America, and additional international jurisdictions participating in metabolic disease studies. Its regulatory interactions include engagement with authorities such as the U.S. Food and Drug Administration and the European Medicines Agency.

While Inventiva does not maintain the large commercial infrastructure of multinational pharmaceutical companies, its development strategy relies on global clinical recruitment and international scientific collaboration. The company’s investor base and market visibility extend into the United States through OTC trading and SEC reporting obligations, alongside its primary listing in France. Inventiva’s international footprint is therefore primarily research- and development-driven rather than commercial in nature.

Leadership & Governance

Inventiva’s leadership team combines pharmaceutical research, biotechnology development, and finance experience. The company has emphasized a strategy focused on scientific specialization, disciplined capital allocation, and advancement of late-stage metabolic disease programs. Governance oversight is provided through a board structure consistent with French public company standards and disclosure practices reflected in annual reports and SEC filings.

Key executives have included:

• Frédéric Cren – Chairman, Chief Executive Officer, and cofounder
• Pierre Broqua, Ph.D. – Chief Scientific Officer and cofounder
• Laurent Olivet – Chief Financial Officer
• Sridhar Prasad, M.D. – Chief Medical Officer
• Nadim Yared – Member of the Board of Directors

Public disclosures indicate that leadership strategy has focused on advancing Inventiva from a research-oriented biotechnology company into a late-stage clinical organization capable of supporting regulatory submission and potential commercialization efforts in MASH and related metabolic diseases.